WASHINGTON — The cardiac myosin inhibitor mavacamten, compared with placebo, reduced the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy, according to results of the VALOR-HCM trial.
Mavacamten (Bristol Myers Squibb) also improved symptoms, biomarker levels and quality of life metrics compared with placebo, Milind Y. Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and director of clinical operations at Cleveland Clinic’s Heart Vascular and Thoracic Institute and professor of medicine at Cleveland Clinic Lerner College of